Protein tau dịch não trong chẩn đoán phân biệt chứng mất trí nhớ

Galton C.J., Patterson K., Xuereb J.H., Hodges J.R., Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases, Brain, 2000, 3, 484–498 McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q., Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease, Arch. Neurol., 2001, 58, 1803–1809 Zhukareva V., Vogelsberg-Ragaglia V., Van Deerlin V.M., Bruce J., Shuck T., Grossman M., et al., Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia, Ann. Neurol., 2001, 49, 165–175 Zhukareva V., Sundarraj S., Mann D., Sjögren M., Blenow K., Clark C.M., et al., Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathol., 2003, 105, 469–476 Itoh N., Arai H., Urakami K., Ishiguro K., Ohno H., Hampel H., et al., Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s disease, Ann. Neurol., 2001, 50, 150–156 Pijnenburg Y.A., Schoonenboom N.S., Rosso S.M., Mulder C., Van Kamp G.J., Van Swieten J.C., et al., CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration, Neurology, 2004, 62, 1649 Schoonenboom N.S., Pijnenburg Y.A., Mulder C., Rosso S.M., Van Elk E.J., Van Kamp G.J., et al., Amyloid β (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease, Neurology, 2004, 62, 1580–1584 De Jong D., Jansen R.W., Pijnenburg Y.A., van Geel W.J., Borm G.F., Kremer H.P., et al., CSF neurofilament proteins in the differential diagnosis of dementia, J. Neurol. Neurosurg. Psychiatry, 2007, 78, 936–938 McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M., Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, Neurology, 1984, 34, 939–944 Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., et al., Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria, Neurology 1998, 51, 1546–1554 Schonknecht P., Pantel J., Werle E., Hartmann T., Essig M., Baudendistel K., et al., Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer’s disease, Fortschr. Neurol. Psychiatr., 2000, 68, 439–446 (in German) The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group, Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”, Neurobiol. Aging, 1998, 19, 109–116 Pijnenburg Y.A., Janssen J.C., Schoonenboom N.S., Petzold A., Mulder C., Stigbrand T., et al., CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer’s disease and controls. Dement. Geriatr. Cogn. Disord., 2007, 23, 225–230 Forman M.S., Zhukareva V., Bergeron C., Chin S.S., Grossman M., Clark C., et al., Signature tau neuropathology in gray and white matter of corticobasal degeneration, Am. J. Pathol., 2002, 160, 2045–2053 Tumani H., Nau R., Felgenhauer K., Beta-trace protein in cerebrospinal fluid: a blood-CSF barrier-related evaluation in neurological diseases, Ann. Neurol. 1998, 44, 882–889 Reiber H., CSF flow — its influence on CSF concentration of brain-derived and blood-derived proteins. In: Teelken A., Korf J. (Eds.), Neurochemistry, Plenum Press, New York, 1997, 423–432 Tapiola T., Overmyer M., Lehtovirta M., Helisalmi S., Ramberg J., Alafuzoff I., et al., The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer’s disease, Neuroreport, 1997, 8, 3961–3963 Riemenschneider M., Wagenpfeil S., Diehl J., Lautenschlager N., Theml T., Heldmann B., et al., Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration, Neurology, 2002, 58, 1622–1628 Fabre S.F., Forsell C., Viitanen M., Sjögren M, Wallin A, Blennow K., et al., Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations, Exp. Neurol., 2001, 168, 413–418 Rosso S.M., van Herpen E., Heutink P., Total tau is not increased in cerebrospinal fluid of frontotemporal dementia patients with P301L and G272V tau mutations, Neurobiol. Aging, 2002, 23, S379 Rosso S.M., van Herpen E., Pijnenburg Y.A., Schoonenboom N.S., Scheltens P., Heutink P., et al., Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations, Arch. Neurol. 2003, 60, 1209–1213 Buée L., Bussière T., Buée-Scherrer V., Delacourte A., Hof P.R., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Rev., 2000, 33, 95–130 Kertesz A., McMonagle P., Blair M., Davidson W., Munoz D.G., The evolution and pathology of frontotemporal dementia, Brain, 2005, 128, 1996–2005 Varma A.R., Snowden J.S., Lloyd J.J., Talbot P.R., Mann D.M., Neary D., Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia, J. Neurol. Neurosurg. Psychiatry, 1999, 66, 184–188 Bürger K., Zinkowski R., Teipel S.J., Tapiola T., Arai H., Blennow K., et al., Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231, Arch. Neurol., 2002, 59, 1267–1272 Hampel H., Teipel S.J., Total and phosphorylated tau proteins: evaluation as core bomarker candidates in frontotemporal dementia, Dement. Geriatr. Cogn. Disord., 2004, 17, 350–354 Blennow K., Vanmechelen E., Hampel H., CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol. Neurobiol., 2001, 24, 87–97 Grossman M., Farmer J., Leight S., Work M., Moore P., Van Deerlin V., et al., Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease, Ann. Neurol., 2005, 57, 721–729 Bürger K., Zinkowski R., Teipel S.J., Arai H., DeBernardis J., Kerkman D., et al., Differentiation of geriatric major depression from Alzheimer’s disease with CSF tau protein phosphorylated at threonine 231, Am. J. Psychiatry, 2003, 160, 376–379 Bian H., Van Swieten J.C., Leight S., Massimo L., Wood E., Forman M., et al., CSF biomarkers in frontotemporal lobar degeneration with known pathology, Neurology, 2008, 70, 1827–1835 Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T., Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease, Acta Neuropathol., 2002;103:26–35. Boban M., Grbić K., Mladinov M., Hof P.R., Süssmair C. Ackl N., et al., Cerebrospinal fluid markers in differential diagnosis of Alzheimer’s disease and vascular dementia, Coll. Antropol., 2008, 32, 31–36 Hampel H., Bürger K., Zinkowski R., Teipel S.J., Görnitz A., Andreasen N., et al., Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study, Arch. Gen. Psychiatry, 2004, 61, 95–102 Matsuo E.S., Shin R.W., Billingsley M.L., Van deVoorde A., O’Connor M., Trojanowski J.Q., et al., Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau, Neuron, 1994, 13, 989–1002